Intensity Therapeutics (NASDAQ: INTS) — Perfil da empresa, notícias e dados financeiros
Intensity Therapeutics focuses on immunotherapy treatments for cancer, using innovative approaches to stimulate immune responses.
Intensity Therapeutics
Intensity Therapeutics (NASDAQ:INTS) is a biotech firm deeply engaged in the development of immunotherapy treatments aimed at a variety of cancers. The company's unique approach involves directly injecting its drug candidates into solid tumors to stimulate an immune response that targets cancer cells throughout the body. Among its notable projects is INT230-6, designed to improve the effectiveness of existing cancer therapies and reduce their side effects. Intensity Therapeutics is keen on transforming cancer treatment by fostering durable responses in advanced and hard-to-treat cancers, demonstrating its commitment to changing the landscape of cancer care through innovation and research.
Resumo
Operações
Produtos e/ou serviços de Intensity Therapeutics
- INT230-6, a lead product designed for direct injection into solid tumors to cause cancer cell death and immune system activation.
- Research collaborations with Merck and Bristol-Myers Squibb to test the combination of INT230-6 with key immunotherapies, aiming to improve cancer treatment outcomes.
- Development of drug delivery technologies focusing on direct tumor injection, aiming to minimize systemic exposure and side effects.
- Pipeline expansion efforts to include novel drug candidates for various types of cancer, leveraging their proprietary drug formulation technology.
- Investigation of INT230-6's mechanism of action to inform the development of next-generation cancer therapies and potentially broaden its applicability.
equipe executiva do Intensity Therapeutics
- Lewis H. BenderFounder, President, CEO & Chairman of the Board
- Joseph TalamoChief Financial Officer
- John WesolowskiPrincipal Accounting Officer & Controller
- James M. AhlersExecutive Vice President of Corporate Finance
Últimas notícias sobre a Intensity Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Intensity Therapeutics, em USD.
- Cap. de mercado
- 11 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -4.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -12 mi | -11,6 mi | |
| 0 | -16,6 mi | -16,3 mi | |
| 0 | -8,3 mi | -10,5 mi | |
| 0 | -7,6 mi | -7,6 mi |